drugset / Trial / NCT00697840
Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of the present trial is to assess the safety, reactogenicity and immunogenicity of adjuvanted hepatitis B vaccine, Engerix™-B and hepatitis B vaccine new formulation when administered at 0, 6 months
Timeline
- Start
- 1995-06
- Primary completion
- 1996-01
- Completion
- 1996-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Engerix-B | Vaccine | — | Intramuscular |
| Subject | HBV-MPL 208129 | Vaccine | — | Intramuscular |
| Subject | Vaccine containing HBsAg absorbed on aluminium salts | Vaccine | — | Intramuscular |